TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06077461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mandala painting
Description: Patients in this group will be subjected to mandala painting.
Study: NCT05480306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: 30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: 90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 90-min IV infusion (5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 90-min IV infusion (5mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: 2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
Study: NCT05675358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
Study: NCT05230875

Intervention type: BEHAVIORAL
Intervention: self-administered questionnaire
Description: All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program.
Study: NCT05302713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ionic Calcium
Description: Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
Study: NCT04258410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral soft chew
Description: placebo identical to experimental drug contained in soft chew

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: experimental drug contained in soft chew
Study: NCT04889664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Repeated intravenous Ketamine infusions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: WET is a brief, 5-session evidence-based written trauma-focused therapy
Study: NCT05638620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stellate ganglion block with 0.5% bupivacaine
Description: The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty.
Study: NCT06394791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + IL-2 Combined with Capox
Description: Tislelizumab + IL-2 Combined with Capox
Study: NCT06424977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomarker Targeted Stimulation (BTS)
Description: Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
Study: NCT04960176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be applied by using 0,25x25mm needles.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive Sham Acupuncture
Description: Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
Study: NCT05623384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial and glossopharyngeal nerve blocks
Description: The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）

Intervention type: DRUG
Group type: OTHER
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8
Study: NCT06545006

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: isometric contractions
Description: Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stroboscopic glasses
Description: This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport.
Study: NCT06405555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
Study: NCT04801329

Intervention type: DRUG
Intervention: Vyndamax (tafamidis 61mg)
Description: As prescribed in real world practice
Study: NCT04831138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI with ASL
Description: T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session.
Study: NCT06545006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quick Release
Description: The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement
Study: NCT05967247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The experimental group used App for MBSR intervention
Description: The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Heart Care Life app
Description: Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app.
Study: NCT06286059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine
Description: In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
Study: NCT05528302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tech-CBT intervention
Description: The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
Study: NCT05021237

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-fractionated radiation therapy
Description: Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
Study: NCT05379790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
Study: NCT05967247

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the Heart Care Life app
Description: Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP
Description: APP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: APP
Description: APP
Study: NCT04856878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
Study: NCT05333458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05165849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFS101A
Description: GFS101A will be administrated intravenously Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
Study: NCT04694248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Study: NCT05379790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
Study: NCT04644185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: all SCTA01 excipients without active component+best supportive care
Study: NCT06163586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neonatal Touch and Massage Therapy
Description: Structured touch and massage therapy performed by certified providers.
Study: NCT04572217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate (starting dose 25 mg daily, max dose 100 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine (starting dose 8 mg, max dose 16 mg)
Study: NCT05379790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
Study: NCT06460948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate-Ethinyl Estradiol
Description: Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate-Ethinyl Estradiol
Description: Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
Study: NCT05379790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
Study: NCT05814432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single high dose of liposomal amphotericin B
Description: Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-AmB standard dose
Description: Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
Study: NCT06130787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and bone marrow sample
Description: Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36
Study: NCT05333458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06043622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography
Description: Optical coherence tomography angiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ophthalmological exam
Description: ophthalmological exam
Study: NCT04732845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fully human anti CD19 CAR-T Cell Dose
Description: Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fully human anti CD19 CAR-T Cell Dose
Description: Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 daily from day -5 to -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 daily from day -5 to -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60mg/Kg on day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60mg/Kg on day -6
Study: NCT06308133

Intervention type: OTHER
Intervention: apheresis procedure
Description: collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)

Intervention type: OTHER
Intervention: apheresis procedure
Description: collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
Study: NCT06441903

Intervention type: OTHER
Intervention: Ultrasound
Description: Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
Study: NCT05118360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41 2 mg
Description: 2mg of ASC41 orally once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41 4 mg
Description: 4mg of ASC41 orally once daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily for 52 weeks.
Study: NCT06121258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video series
Description: The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.